#USA #New York #Class Action #Rosen Law Firm #Capricor Therapeutics

Capricor Therapeutics Securities Class Action Opportunity

Overview

The Rosen Law Firm, a well-known entity in investor rights law, is reaching out to individuals who purchased shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) from October 9, 2024, to July 10, 2025. This outreach is significant as claims of securities fraud have surfaced, leading to an ongoing class action lawsuit. Investors must take action as the deadline to assume the role of lead plaintiff is September 15, 2025.

Important Dates and Actions

If you acquired Capricor securities within this specified period, you could claim compensation without incurring any upfront fees, thanks to a contingency fee arrangement. To participate, interested investors can visit the Rosen Law Firm's website or connect directly with attorney Phillip Kim at 866-767-3653 or via email at [email protected].

Deadlines to Remember

• - Class Period: October 9, 2024 - July 10, 2025
• - Lead Plaintiff Deadline: September 15, 2025

Why Join the Class Action

The class action lawsuit has been initiated based on allegations that Capricor's executives misled investors regarding their leading drug candidate, deramiocel, which is targeted for cardiomyopathy linked to Duchenne muscular dystrophy (DMD). Throughout the Class Period, important assertions regarding the ability to secure a Biologics License Application (BLA) from the FDA for deramiocel were promoted, yet these claims were veiled in misleading information about the drug's safety and efficacy data from critical clinical trials. The suit suggests that this misrepresentation inflated the stock prices, resulting in losses for shareholders once the truth emerged.

Protecting Investor Rights

Rosen Law Firm emphasizes the importance of selecting a qualified legal representative for those affected. While many firms announce these cases, only some have the proven experience and success rates to navigate securities class actions effectively. The firm has an impressive history, recovering substantial amounts for investors, including over $438 million in a single year (2019), and being consistently rated among the top legal practices in this field.

Noteworthy Achievements

• - Ranked #1 by ISS Securities Class Action Services for the number of settlements in 2017.
• - Attained the largest securities class action settlement against a Chinese company at that time.
• - Notable recognition of founders and attorneys by prestigious legal bodies.

Allegations Against Capricor

According to the lawsuit, Capricor’s management misled shareholders by providing excessively optimistic updates about deramiocel while hiding unfavorable data concerning its Phase 2 HOPE-2 trial outcomes. The failure to disclose critical safety and efficacy issues associated with deramiocel ultimately misled investors, leading them to believe in inflated stock valuations. When the truth about the product became apparent, stock prices reflected the harsh reality, contributing to economic losses for the shareholders.

Next Steps for Investors

Participants in this class action may either assert their rights as a lead plaintiff or remain as absent class members. It's crucial to remember that joining the action does not require you to serve as the lead plaintiff; however, if you wish to guide the litigation process, action must be initiated by the lead plaintiff deadline.
For continuous updates, investors are encouraged to follow the Rosen Law Firm on social platforms, including LinkedIn, Twitter, and Facebook.

Final Thoughts

This class action presents an essential opportunity for Capricor investors to claim compensation and hold the company accountable for any securities fraud. Stay informed and consider your options carefully as the deadline approaches.